Nls pharmaceutics and kadimastem announce pricing and closing of $1 million equity financing

Accumulated proceeds of $3 million including the initial closing held in march 2025 zÜrich, june 30, 2025 /prnewswire/ -- nls pharmaceutics ltd . (nasdaq: nlsp) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (cns) disorders, today announced that it has completed the second and final $1 million closing of its previously disclosed $3 million equity financing of preferred shares (or equivalents) and warrants from march 2025.
NLSP Ratings Summary
NLSP Quant Ranking